Intravitreal injection is fast, familiar, and highly effective, which is why it remains the default for retinal delivery. But its safety, immune, and physiological limits cap how far conventional IVT can really go.
As retinal therapies grow larger and more complex, it’s time to look beyond IVT while there’s still room to manoeuvre. David Cottenden from TTP’s Drug Delivery team unpacks this in the video below.
.jpg)
